| Clarivate Report Reveals Top Trademark Portfolios |
Procter & Gamble, Nestlé, Apple, L'Oréal, Novartis, LG Electronics and Unilever among the largest portfolio owners in most registers LONDON , May 15, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Trademark filing trends 2025 report, analyzing ten key trademark registers worldwide: the United States (U.S.), Canada, the United Kingdom (U.K.), the European Union (EU), France, Germany, India, Mainland China, Japan, and Australia. The report reveals the top 20 largest local and foreign-based trademark portfolios in each region and the law firms managing the largest trademark portfolios. |
prnewswire.com |
2025-05-15 07:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments |
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON , May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process. |
prnewswire.com |
2025-05-14 08:00:00 |
Czytaj oryginał (ang.) |
| Clarivate: Organic Growth Has Reached A Potential Inflection Point |
I rate Clarivate a buy, as 1Q25 marks a potential turning point with positive organic growth driven by stronger renewals and a healthier recurring revenue mix. CLVT's recurring revenue now makes up 83% of total sales, with organic recurring revenue growing by 0.6% y/y, indicating improved fundamentals. The IP segment shows promise, with 1.3% y/y organic growth, driven by stronger patent renewals and new AI tools like Derwent's AI-powered search feature. |
seekingalpha.com |
2025-05-03 08:33:17 |
Czytaj oryginał (ang.) |
| Life Science Analytics Market worth $68.81 billion by 2030 11.4% CAGR | MarketsandMarkets™ |
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particularly for applications such as patient recruitment and site identification, helps to reduce the workload for researchers and investigators. These factors contribute significantly to the growing adoption of analytics across the life sciences industry. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 Browse in-depth TOC on "Life Science Analytics Market" 100 - Tables50 - Figures500 - Pages By Based on type, the life science analytics services market is categorized into two main types: managed services and professional services. In 2024, the managed services segment held the largest share of the life science analytics market. This significant share is largely due to the increasing demand for advanced insights, the need for cost-effective drug development, technological advancements in the industry, and the necessity for ongoing support in strategic decision-making. These factors make outsourcing analytics and consulting more attractive for life science companies. Leading companies in the field offer consulting services that leverage data and analytics to evaluate opportunities, design analytics strategies, and implement appropriate technology solutions. For instance, in May 2023, SAS Institute (US) partnered with HTEC (US) to deliver strategic analytics consulting services across various sectors, including life sciences and healthcare. By Based on applications, The life science analytics market is divided into several applications, including research & development, commercial analytics, regulatory compliance, manufacturing and supply chain optimization, and safety. In 2024, the research & development segment held the largest share of this market. This significant share is mainly due to its capacity to accelerate drug discovery, optimize clinical trials, and improve research accuracy through advanced data analysis and AI-driven insights. Additionally, factors such as increasing R&D expenditure in the pharmaceutical and biopharmaceutical sectors, a rise in patent expirations and declining drug pipelines, and a growing focus on personalized medicine and precision therapeutics are further driving growth in this segment. By geography, the life science analytics market is divided into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience significant growth, with a noticeable annual growth rate during the forecast period. Key factors driving the expansion of life science analytics solutions in this region include a gradual shift towards adopting advanced technologies such as automation, artificial intelligence (AI), and machine learning (ML). Additionally, rising investments are attracting new market players, and the presence of leading educational institutions and research centers in Asia Pacific is fostering scientific innovation and technological advancement. Furthermore, increased direct investments from pharmaceutical and biotechnology companies in Europe and North America are anticipated to boost the adoption of life science analytics solutions in Asia. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653 Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US), Microsoft (US), MaxisIT (US), ExlService Holdings (US), Inovalon (US), CitiusTech (US), Saama (US), Axtria (US), Clarivate (UK), ThoughtSphere (US), ThoughtSpot (US), Salesforce (US), Google LLC (US), Amazon Web Services, Inc. (US), Veeva Systems (US), Elsevier (Netherlands), and Komodo Health, Inc. (US) are the major players in this market. These companies mainly focus on strategies such as acquisitions, collaborations, partnerships, expansion, and product launches and updates to remain competitive and further increase their share in the market. ORACLE (US): Oracle (US) is a leading company in life science analytics worldwide. The company offers analytics software and services for various applications, including research & development, commercialization, and more. Oracle is committed to continuously updating its products to meet customer expectations. Additionally, the company invests in expanding its solutions through partnerships and collaborations, ensuring tailored solutions for its users. In March 2025, Oracle partnered with Huntsville Hospital Health System (US) to standardize its Oracle Health Foundation electronic health record system across all facilities. This collaboration aims to provide consistent, high-quality care and a unified experience for both patients and providers as they move between different locations. With a broad customer base and a significant geographic presence, Oracle is a critical player in various IT software, hardware, and service markets, including life science analytics. MERATIVE (US): Merative (US) is another leading player in the life science analytics market. The company offers a comprehensive suite of informatics products and services tailored for life science analytics. By leveraging advanced technologies such as AI and ML, Merative enhances the accuracy and efficiency of evidence analysis. Its strong brand recognition and extensive product portfolio have significantly contributed to its success. Merative serves various sectors, including life science systems, clinical trial sponsors, and the medical device manufacturing industry. Additionally, the company has established offices across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. SAS INSTITUTE INC. (US) SAS Institute Inc. (US) is a company that specializes in analytics software and services. It offers a wide range of solutions, including advanced analytics, business intelligence, cloud analytics, customer intelligence, data operations, data management, decision management, fraud and security intelligence, in-memory analytics, performance management, risk management, and supply chain management. These solutions enable organizations to access, manage, analyze, and report on data to support informed decision-making. SAS Institute serves various industries, including communications, education, financial services, government, health insurance, healthcare, hospitality, insurance, life sciences, manufacturing, media, oil and gas, retail, travel and transportation, and utilities. Through its Life Sciences industry segment, the company also provides specialized analytics solutions for the life sciences sector. By leveraging AI and analytics driven by fast and relevant data, SAS aims to propel innovation in health and life sciences. The company supports customers in 146 countries across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. More than 82,000 business, government, and university sites utilize SAS OnDemand for Academics. For more information, Inquire Now! Related Reports: Healthcare Analytics Market Healthcare BPO Market Healthcare IT Market Artificial Intelligence (AI) in Healthcare Market Healthcare Data Monetization Market Get access to the latest updates on Life Science Analytics Companies and Life Science Analytics Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-05-02 14:30:00 |
Czytaj oryginał (ang.) |
| Clarivate Plc (CLVT) Q1 2025 Earnings Call Transcript |
Clarivate Plc (NYSE:CLVT ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Mark Donohue - Vice President, Investor Relations Matti Shem Tov - Chief Executive Officer Jonathan Collins - Chief Financial Officer Conference Call Participants Greg Parrish - Morgan Stanley David Paige - RBC Capital Markets Shlomo Rosenbaum - Stifel George Tong - Goldman Sachs Surinder Thind - Jefferies Operator Thank you for joining ladies and gentlemen. My name is Karen, I'll be your conference operator. |
seekingalpha.com |
2025-04-29 17:09:47 |
Czytaj oryginał (ang.) |
| Clarivate (CLVT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-29 14:36:04 |
Czytaj oryginał (ang.) |
| Clarivate PLC (CLVT) Q1 Earnings and Revenues Surpass Estimates |
Clarivate PLC (CLVT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.14 per share a year ago. |
zacks.com |
2025-04-29 12:15:33 |
Czytaj oryginał (ang.) |
| Clarivate Reports First Quarter 2025 Results |
— Accelerated recurring organic revenue growth — — Reaffirmed 2025 Outlook — — Repurchased $50 million ordinary shares — LONDON , April 29, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2025. Total revenues for the first quarter of 2025 was $593.7 million, compared to total revenues of $621.2 million for the first quarter of 2024. |
prnewswire.com |
2025-04-29 10:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and Execution |
New solution provides integrated provider intelligence and real-world data to optimize targeting, strategic planning and patient access across commercial organizations LONDON , April 23, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Commercial Analytics 360—a solution designed to empower medtech companies with advanced insights to drive commercial performance. As the demand for precise, analytics-driven strategies grows, medtech companies require deeper visibility into customer activity, affiliations, practice behavior and caseloads. |
prnewswire.com |
2025-04-23 08:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Releases EndNote 2025 with AI-Powered Research Tools |
Enhancing research efficiency and accuracy with newly integrated features LONDON , April 23, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released EndNote 2025, a comprehensive reference management solution that streamlines the research and writing process. Its new features include AI support, enhanced referencing tools, and journal matching capabilities, designed to save researchers time and improve accuracy. |
prnewswire.com |
2025-04-23 07:00:00 |
Czytaj oryginał (ang.) |
| Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Should You Buy? |
Clarivate (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-22 15:06:27 |
Czytaj oryginał (ang.) |
| Clarivate to Report First Quarter 2025 Results on April 29, 2025 |
LONDON , April 2, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the first quarter 2025 before the market opens on Tuesday, April 29, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. |
prnewswire.com |
2025-04-02 12:05:00 |
Czytaj oryginał (ang.) |
| Clarivate Partners with Iprova to Streamline the Invention Creation and Submission Process |
The partnership will see Iprova's suite of solutions integrated with IP management software IPfolio LONDON , March 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with Iprova, the world's first data-driven invention company and developer of state-of-the-art Artificial Intelligence-based technologies which augment and enhance the human ability to invent. This partnership will combine Iprova's product suite for collaboratively capturing, creating and refining inventive concepts with IPfolio, the industry-leading IP management software, enabling a smooth transition of inventions into the patent workflow. |
prnewswire.com |
2025-03-18 06:00:00 |
Czytaj oryginał (ang.) |
| TE Connectivity ranks among Clarivate Top 100 Global Innovators 2025 |
List highlights organizations at the forefront of technology research and innovation GALWAY, Ireland , March 12, 2025 /PRNewswire/ -- TE Connectivity, a world leader in connectors and sensors, has been named among the Clarivate Top 100 Global Innovators, an annual list of organizations that prioritize innovation as a business strategy. Innovation is a core value at TE, which has been named a Top 100 Global Innovator 12 times since Clarivate created the recognition in 2012. |
prnewswire.com |
2025-03-12 09:04:00 |
Czytaj oryginał (ang.) |
| Philips highest ranked medical technology company among Clarivate Top 100 Global Innovators |
March 12, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in the Top 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years. Roy Jakobs, CEO of Royal Philips said: "At Philips, we've been innovating for over 130 years to improve people's lives. Innovation is our fundamental strength, the reason why customers choose us as their strategic partner and a key value driver for our company. Our portfolio of patient- and people-centric innovations in hardware, software, AI and services drives healthcare productivity and empowers people to look after their health and well-being – delivering better care for more people." In 2024, Philips invested approximately EUR 1.7 billion – or an industry leading >9% of sales – in research and development to help drive better care for more people. Philips is increasingly focusing its innovation efforts on the potential of data and AI, both in hospital settings and at home. As a leader in AI-related patent applications in healthcare, Philips dedicates around half of its R&D workforce to these fields. Examples of Philips' AI-powered innovations that increase caregiver productivity and deliver better care for more people include: |
globenewswire.com |
2025-03-12 07:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Reveals Top 100 Global Innovators 2025 |
The Top 100 organizations generate $4.6 trillion USD in annual revenues, representing 4.4% of the global economy LONDON , March 12, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2025 ranked list of Top 100 Global Innovators – the organizations at the forefront of technology research and innovation worldwide. The Top 100 organizations prioritize innovation as a central part of their business strategy. |
prnewswire.com |
2025-03-12 06:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America |
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON , Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing? , shedding light on the pharmaceutical industry's evolution in the region. |
prnewswire.com |
2025-02-27 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Plc (CLVT) Q4 2024 Earnings Call Transcript |
Clarivate Plc (NYSE:CLVT ) Q4 2024 Earnings Conference Call February 19, 2025 9:00 AM ET Company Participants Mark Donohue - VP of IR Matti Shem Tov - CEO Jonathan Collins - CFO Conference Call Participants Manav Patnaik - Barclays Andrew Nicholas - William Blair George Tong - Goldman Sachs Owen Lau - Oppenheimer Shlomo Rosenbaum - Stifel Surinder Thind - Jefferies Peter Christiansen - Citi Ashish Sabadra - RBC Capital Markets Operator Thank you for standing by. My name is Kate, and I will be your conference operator today. |
seekingalpha.com |
2025-02-19 17:55:59 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Clarivate (CLVT) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-19 12:35:48 |
Czytaj oryginał (ang.) |
| Clarivate PLC (CLVT) Q4 Earnings and Revenues Top Estimates |
Clarivate PLC (CLVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.23 per share a year ago. |
zacks.com |
2025-02-19 10:11:13 |
Czytaj oryginał (ang.) |
| Clarivate Reports Fourth Quarter and Full Year 2024 Results |
— Accelerates transition from transactional to subscription and re-occurring revenue — — Launches new product innovation for Academia & Government and Life Sciences & Healthcare — — Repurchased $200 million ordinary shares and pre-paid $198 million of debt in 2024 as part of balanced capital allocation strategy — — Initiates review of strategic alternatives including potential divestitures — — Provides 2025 Outlook — LONDON , Feb. 19, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2024. Total revenue for the fourth quarter of 2024 was $663.0 million, compared to total revenue of $683.7 million in the fourth quarter of 2023. |
prnewswire.com |
2025-02-19 08:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Unveils Transformative Subscription-Based Access Strategy for Academia |
New approach enables broad, simple and affordable access to trusted scholarly content for learning and research LONDON , Feb. 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a new subscription-based content access strategy. The new approach breaks down barriers through broad and affordable access to highly curated, trusted academic resources, including Ebooks and primary digital collections, enabling every library to support research, teaching and learning goals. |
prnewswire.com |
2025-02-18 05:00:00 |
Czytaj oryginał (ang.) |
| Exploring Analyst Estimates for Clarivate (CLVT) Q4 Earnings, Beyond Revenue and EPS |
Beyond analysts' top -and-bottom-line estimates for Clarivate (CLVT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:50 |
Czytaj oryginał (ang.) |
| Clarivate Recognized for Excellence in Trademark Business in the WTR 1000 2025 |
Highly recommended in trademark management, searching and watching, renewals and recordals LONDON , Feb. 10, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been recognized by the World Trademark Review for three categories in the WTR 1000 2025 . This guide identifies the top trademark professionals and firms in key jurisdictions around the globe. |
prnewswire.com |
2025-02-10 11:30:00 |
Czytaj oryginał (ang.) |
| Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform |
Software-as-a-Service, cloud-based library services and discovery platform to be implemented in nine universities and 82 academic and research libraries across Croatia LONDON , Feb. 5, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that the National and University Library in Zagreb has selected Clarivate to provide its unified library services and discovery platform. The National and University Library in Zagreb (NSK) is Croatia's leading cultural and research institution, serving as both the National Library of Croatia and the University of Zagreb's main library. |
prnewswire.com |
2025-02-05 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Reveals Medtech Breakthroughs Driving Growth in Pulsed Field Ablation Market |
New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment LONDON , Feb. 4, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence and BioWorld by Clarivate, today published a new e-book, Pulsed field ablation: stunning growth shocks the atrial fibrillation market . The Clarivate e-book highlights new medtech breakthroughs in the pulsed field ablation (PFA) market, forecasting its future growth and showcasing the technology's potential to transform the treatment paradigm for atrial fibrillation. |
prnewswire.com |
2025-02-04 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate identifies top 50 universities powering global innovation |
Report from the Institute for Scientific Information shows how academic research drives global innovation and benefits society LONDON , Jan. 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released The top 50 universities powering global innovation report which analyzes the critical role of research in shaping global industrial innovation and societal impact, using data and expert insights derived from academic research and patent citations. Drawing on a host of Clarivate data - from the Web of Science to Derwent World Patents Index, and Derwent Patents Citation Index – the report highlights how knowledge flows between academia and industry across countries and regions, underscoring the global nature of innovation. |
prnewswire.com |
2025-01-30 05:00:00 |
Czytaj oryginał (ang.) |
| The British Library Selects Clarivate to Provide Library Services and Discovery Platforms |
Achieving more unified and secure workflows with cloud-based Alma, Primo and Rapido library software solutions from Clarivate LONDON , Jan. 28, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces that the British Library has selected Clarivate to provide its library services and discovery platforms to create a more cohesive, streamlined and secure experience. The British Library will implement Alma, Primo VE and Rapido. |
prnewswire.com |
2025-01-28 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate to Report Fourth Quarter and Full Year 2024 Results on February 19, 2025 |
LONDON , Jan. 22, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the fourth quarter and full year 2024 before the market opens on Wednesday, February 19, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. |
prnewswire.com |
2025-01-22 10:45:00 |
Czytaj oryginał (ang.) |
| Does Clarivate (CLVT) Have the Potential to Rally 29.13% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Clarivate (CLVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-16 13:01:25 |
Czytaj oryginał (ang.) |
| BioWorld by Clarivate Releases Comprehensive 2024 Year in Review |
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON , Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025. |
prnewswire.com |
2025-01-16 05:00:00 |
Czytaj oryginał (ang.) |
| Post-marketing Pharmacovigilance and Medical Information Market Research 2024: Rising Adverse Drug Reactions (ADRs) and Expanding Use of Biologics and Specialty Drugs Fueling Growth - Forecast to 2034 |
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034. |
globenewswire.com |
2025-01-14 13:40:00 |
Czytaj oryginał (ang.) |
| Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data |
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON , Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes — eliminating the complexities of raw data management. |
prnewswire.com |
2025-01-14 05:10:00 |
Czytaj oryginał (ang.) |
| Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report |
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON , Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years. |
prnewswire.com |
2025-01-08 05:05:00 |
Czytaj oryginał (ang.) |
| Clarivate Announces New $500 Million Share Repurchase Authorization |
LONDON , Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024. |
prnewswire.com |
2024-12-16 10:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Launches AI-Powered Patent Search Solution in Derwent |
Faster and more relevant results to empower critical IP decision-making LONDON , Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time. |
prnewswire.com |
2024-12-12 05:00:00 |
Czytaj oryginał (ang.) |
| Bargains Galore? 3 Stocks With Insider Buying in the Millions |
It's widely believed that insiders know how well a company is operating. Therefore, when insiders are actively buying their stock, it is assumed they must know something that's motivating them to buy shares. |
marketbeat.com |
2024-12-10 10:00:20 |
Czytaj oryginał (ang.) |
| Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts |
Revealing highly active specialties in sciences and social sciences LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today. |
prnewswire.com |
2024-11-27 10:00:00 |
Czytaj oryginał (ang.) |
| Daikin Selects IPfolio from Clarivate |
Enhancing operational efficiency for leading air conditioner manufacturer LONDON , Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate. |
prnewswire.com |
2024-11-27 05:00:00 |
Czytaj oryginał (ang.) |
| BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series |
New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON , Nov. 21, 2024 /PRNewswire/ -- BioWorld ™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide. ' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment. |
prnewswire.com |
2024-11-21 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Reveals Highly Cited Researchers 2024 List |
Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON , Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researchers in 2024 from more than 1,200 institutions in 59 nations and regions. |
prnewswire.com |
2024-11-19 05:00:00 |
Czytaj oryginał (ang.) |
| New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence |
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON , Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come . Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. |
prnewswire.com |
2024-11-18 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Healthcare Business Insights Unveils 2023 Revenue Cycle Award Winners |
Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital Groups LONDON , Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPIs, based on data from their most recent and preceding full fiscal years. |
prnewswire.com |
2024-11-13 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Publishes 2023 Sustainability Report |
LONDON , Nov. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has today published its fourth annual sustainability report, showcasing its commitment to sustainability and the United Nations Sustainable Development Goals (SDGs). In 2023, Clarivate was shortlisted for the SDG Pioneer Award at the Thomson Reuters Responsible Business Awards. |
prnewswire.com |
2024-11-12 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate: Downgrade To Hold As Growth May Take A Long Time To Recover |
I downgrade Clarivate PLC from buy to hold due to lack of confidence in near-term organic growth recovery and potential further stock price decline. CLVT's 3Q24 earnings report showed a 3.9% revenue decline and worsening organic growth, marking the worst performance in its history. The new CEO's Value Creation Plan is promising but will take a long time to show results, adding to the uncertainty. |
seekingalpha.com |
2024-11-08 10:04:35 |
Czytaj oryginał (ang.) |
| Clarivate Launches New Sustainability Research Solution |
ProQuest One Sustainability offers a transdisciplinary research experience and features AI-powered ProQuest Research Assistant LONDON , Nov. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of ProQuestTM One Sustainability. The new solution is an expansive, curated, multi-format content collection designed to meet the growing demand for sustainability curricula across research, teaching and learning. |
prnewswire.com |
2024-11-07 05:00:00 |
Czytaj oryginał (ang.) |
| Clarivate Plc (CLVT) Q3 2024 Earnings Call Transcript |
Clarivate Plc (NYSE:CLVT ) Q3 2024 Earnings Conference Call November 6, 2024 9:00 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Matti Shem Tov - Chief Executive Officer Jonathan Collins - Chief Financial Officer Conference Call Participants Owen Lau - Oppenheimer David Paige - RBC Toni Kaplan - Morgan Stanley Andrew Nicholas - William Blair Manav Patnaik - Barclays Shlomo Rosenbaum - Stifel Peter Christiansen - Citi George Tong - Goldman Sachs Colton Feldmann - Jefferies Operator Hello, and thank you for standing by. My name is Regina and I will be your conference operator today. |
seekingalpha.com |
2024-11-06 17:07:46 |
Czytaj oryginał (ang.) |
| Clarivate (CLVT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 12:35:47 |
Czytaj oryginał (ang.) |
| Clarivate PLC (CLVT) Matches Q3 Earnings Estimates |
Clarivate PLC (CLVT) came out with quarterly earnings of $0.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.21 per share a year ago. |
zacks.com |
2024-11-06 10:10:22 |
Czytaj oryginał (ang.) |
| Clarivate Reports Third Quarter 2024 Results |
LONDON , Nov. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenues of $622.2 million decreased 3.9% Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6% Net loss of $65.6 million; Net loss per diluted share of $0.09 Adjusted net income(1) of $134.1 million decreased 12.1%; Adjusted diluted EPS(1) of $0.19 decreased 9.5% or $0.02 Adjusted EBITDA(1) of $264.4 million decreased 6.0%; Adjusted EBITDA margin(1) of 42.5% decreased 100 basis points primarily due to lower revenues Net cash provided by operating activities of $202.9 million increased $39.5 million; Free cash flow(1) of $126.3 million increased $24.6 million primarily due to the timing of working capital Nine Months Ended September 30, 2024 Financial Highlights Revenues of $1,893.7 million decreased 2.6% Organic revenues decreased 1.5% as an increase in subscription revenues of 1.2% was offset by a decline in re-occurring revenues of 2.3% and transactional and other revenues of 9.3% Net loss of $444.9 million; Net loss per diluted share of $0.69 Adjusted net income(1) of $379.8 million decreased 12.8%; Adjusted diluted EPS(1) of $0.52 decreased 11.9% or $0.07 Adjusted EBITDA(1) of $775.1 million decreased 5.4%; Adjusted EBITDA margin(1) of 40.9% decreased 120 basis points primarily due to lower revenues Net cash provided by operating activities decreased $48.0 million to $505.3 million; Free cash flow(1) decreased $76.3 million to $298.4 million primarily due to lower operating income and increased capital expenditures "Clarivate's third quarter results are unsatisfactory and reflect an overdependency on fluctuating transactional revenue and areas of the business with low margin characteristics," said Matti Shem Tov, Chief Executive Officer. |
prnewswire.com |
2024-11-06 08:00:00 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Clarivate (CLVT) Q3 Earnings |
Get a deeper insight into the potential performance of Clarivate (CLVT) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2024-11-05 12:20:42 |
Czytaj oryginał (ang.) |
| Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Clarivate (CLVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:06:49 |
Czytaj oryginał (ang.) |
| Thompson Street Portfolio Company Silverchair Announces Agreement to Acquire Scholarone |
ST. LOUIS--(BUSINESS WIRE)--Silverchair, a portfolio company of Thompson Street Capital Partners (TSCP), announced today that is has entered into a definitive agreement with Clarivate Plc (NYSE:CLVT) to acquire ScholarOne, a leading provider of software and services to scholarly publishers and societies. Terms of the transaction were not disclosed. Founded in 1993 and based in Charlottesville, VA, Silverchair provides a suite of software and services to leading global publishers of scientific,. |
businesswire.com |
2024-10-29 08:30:00 |
Czytaj oryginał (ang.) |
| Clarivate to Report Third Quarter 2024 Results on November 6, 2024 |
LONDON , Oct. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the third quarter 2024 before the market opens on Wednesday, November 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. |
prnewswire.com |
2024-10-16 12:30:00 |
Czytaj oryginał (ang.) |